EyePoint Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $355.18 Mil.
During the past 12 months, EyePoint Pharmaceuticals's average Total Assets Growth Rate was -32.60% per year.
During the past 3 years, the average Total Assets Growth Rate was -19.80% per year.
During the past 5 years, the average Total Assets Growth Rate was -6.90% per year.
During the past 10 years, the average Total Assets Growth Rate was 34.10% per year.
During the past 13 years, EyePoint Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 243.60%. The lowest was -43.00%. And the median was -14.00%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
EyePoint Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EyePoint Pharmaceuticals (NAS:EYPT) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
EyePoint Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
EyePoint Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
EyePoint Pharmaceuticals (EyePoint Pharmaceuticals) Business Description
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EYPT has been successfully added to your 